Abatacept now approved for rheumatoid arthritis after failure of conventional DMARDs

Following a review, NICE have overturned their previous negative decision for abatacept (Orencia) following the introduction of a patient access scheme.

This new guidance brings the drug in line with other anti-TNF drugs licensed for the treatment of rheumatoid arthritis (pictured) that have been approved by NICE for NHS use | SCIENCE PHOTO LIBRARY
This new guidance brings the drug in line with other anti-TNF drugs licensed for the treatment of rheumatoid arthritis (pictured) that have been approved by NICE for NHS use | SCIENCE PHOTO LIBRARY

Previously, abatacept was only approved for use in rheumatoid arthritis after the failure of a TNF inhibitor. Now it may also be used in adults whose disease has responded inadequately to 2 conventional disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate, provided the manufacturer supplies abatacept with the discount agreed in the patient access scheme.

View Orencia drug record

NICE guidance on abatacept in rheumatoid arthritis after failure of conventional DMARDS

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Early emollient use does not prevent eczema in children, studies show

Early emollient use does not prevent eczema in children, studies show

Daily application of emollients in infancy is not effective...

Macrolide prescribing in pregnancy linked to risk of birth defects

Macrolide prescribing in pregnancy linked to risk of birth defects

Researchers have called for caution when prescribing...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Ativan and penicillamine.
Use our constantly...